Sarlósejtes vérszegénység: vizsgálatok itt: Kenya
5 trials · From ClinicalTrials.gov, checked 2026. november 16.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
- Where
- Ahero, Eldoret, Kisumu, Siaya
- Életkor
- 12 év to 100 év
- People
- 354 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06439082 - 2. fázisTaking peopleA Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
- Where
- Kericho, Kisumu, Siaya
- Életkor
- 6 hónap to 18 év
- People
- 95 worldwide
- Run by
- Forma Therapeutics, Inc.
See details and how to joinNCT06198712 · EU 2024-519881-32-00 - 3. fázisTaking peopleA Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
- Where
- Kericho, Kisumu, Nairobi, Siaya
- Életkor
- 2 év and over
- People
- 480 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT06609226 · EU 2024-510805-27-00 - 3. fázisNot yet taking people in KenyaA Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
- Where
- Eldoret, Kisumu, Nairobi, Siaya
- Életkor
- 12 év and over
- People
- 510 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT06612268 · EU 2023-509175-16-00 - 2/3. fázisBefejeződöttA Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
- Where
- Kisumu, Nairobi
- Életkor
- 12 év to 64 év
- People
- 389 worldwide
- Run by
- Pfizer
See details and how to joinNCT05431088 · EU 2023-508766-14-00